Arcede Pharma is in full swing with the preparations for clinical studies with drug candidate RCD405. CEO Mia Lundblad has announced that she will leave her position for a more research-oriented role outside the company. Lundblad will continue as CEO until the beginning of February, when the company's CFO Erik Magnusson will take over as acting CEO.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0098 SEK | -10.91% |
|
-5.77% | -89.23% |
2023 | Arcede Pharma Announces CEO Changes | CI |
2023 | Arcede Pharma and Iconovo AB Takes the Next Step in the Development of a New Treatment for COPD | CI |
- Stock Market
- Equities
- ARCEDE Stock
- News Arcede Pharma AB
- Arcede Pharma Announces CEO Changes